Related Experiment Videos
Single lung transplantation in patients with systemic disease
S M Levine1, A Anzueto, J I Peters
1Department of Medicine (Division of Pulmonary Diseases), University of Texas Health Science Center at San Antonio.
Chest
|March 1, 1994
Summary
Single lung transplantation (SLT) offers significant functional improvement for patients with end-stage lung disease due to systemic conditions or prior malignancy. Carefully selected candidates can achieve good outcomes and survival rates comparable to the general SLT population.
Area of Science:
- Pulmonary Medicine
- Transplant Surgery
- Immunology
Background:
- Systemic diseases and prior malignancies are traditionally contraindications for single lung transplantation (SLT).
- End-stage lung disease from these conditions presents unique challenges for surgical intervention.
- Evaluating the efficacy of SLT in these specific patient groups is crucial for expanding treatment options.
Observation:
- A case series of nine patients undergoing SLT for pulmonary involvement from sarcoidosis, scleroderma, or prior malignancies was analyzed.
- Patients were assessed using pulmonary function tests, exercise oximetry, and ventilation-perfusion lung scans.
- Actuarial survival rates were calculated and compared to a larger SLT cohort.
Findings:
- All patients demonstrated marked improvements in pulmonary function and exercise capacity post-SLT.
- Seven of the nine patients returned to full daily activities without pulmonary disability.
- The 1- and 2-year actuarial survival rates were 68.6%, comparable to the overall SLT group (66.3% and 55.8%).
- No evidence of recurrent malignancy was observed in patients with prior malignancies.
Implications:
- Carefully selected patients with lung disease secondary to systemic conditions or chemotherapy-induced fibrosis may benefit from SLT.
- SLT can be a viable option for patients previously excluded due to contraindications.
- This study supports the expansion of SLT indications in select complex cases.